



COPY
PATENT
Attorney Docket No: 05558.0011.NPUS04

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Stephen S. Palmer
App. No.: 10/817,312
Confirmation No.: 1876
Filing Date: April 1, 2004
Title: INHIBITORS OF
PHOSPHODIESTERASES IN
INFERTILITY
Art Unit: 1653

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date:

July 30, 2004
Date

Teddy C. Scott
Teddy C. Scott
Registration No. 53,573

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes art under 35 U.S.C. §102 or §103.

This Information Disclosure Statement is submitted before the mailing of a first Office Action in connection with the merits for the above-identified patent application. Consequently, pursuant to 37 C.F.R. § 1.97 (b)(4), we do not believe any fee is due with the submission of this

Information Disclosure Statement. However, should any fees be deemed necessary in connection with the filing of this paper, the Commissioner is hereby authorized to deduct any such fees from Howrey Simon Arnold & White, LLP's Deposit Account No. 08-3038.

Respectfully submitted,

HOWREY SIMON ARNOLD & WHITE, LLP

By: 

Teddy C. Scott, Jr., Ph.D.
Registration No.: 53,573

Dated: July 30, 2004

HOWREY SIMON ARNOLD & WHITE, LLP
321 N. Clark Street, Suite 3400
Chicago, IL 60661
(312) 595-1239 (main)
(312) 846-5621 (direct)
(312) 595-2250 (fax)



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|-------------------------------|-------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/817,312 |
| | | | | Filing Date | April 1, 2004 |
| | | | | First Named Inventor | Stephen S. Palmer |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 1 | of | 13 | Attorney Docket Number | 05558.0011.NPUS04 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number – Kind Code ² (if known) | | | |
| | A1 | 2002/0103106 A1 | 08/01/2002 | Palmer, et al | |
| | A2 | 2003/0018037 A1 | 01/23/2003 | Simon Lempriere, et al. | |
| | A3 | 5,703,098 | 12/30/1997 | Muller, et al. | |
| | A4 | 5,739,144 | 04/14/1998 | Warrelow, et al. | |
| | A5 | 5,767,067 | 06/16/1998 | Arpaia, et al. | |
| | A6 | 6,127,363 | 10/03/2000 | Doherty, Jr., et al. | |
| | A7 | 6,624,181 B1 | 09/23/2003 | Kilian, et al. | |
| | A8 | 6,649,633 B2 | 11/18/2003 | Chambers, et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|--|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ – Number ⁴ – Kind Code ⁵ (if known) | | | | |
| | B1 | DE 1545687 | 08/07/1969 | | | |
| | B2 | DE 20208869 | 12/23/1970 | | | |
| | B3 | DE 2123328 | 12/02/1971 | | | |
| | B4 | DE 2315801 | 10/11/1973 | | | |
| | B5 | DE 2402908 | 07/24/1975 | | | |
| | B6 | DE 2413935 | 10/16/1975 | | | |
| | B7 | DE 3900233 | 07/20/1989 | | | |
| | B8 | EP 0103497 | 01/29/1986 | | | |
| | B9 | EP 0139464 | 01/02/2004 | | | |
| | B10 | EP 0158380 | 01/11/1989 | | | |
| | B11 | EP 0163965 | 11/08/1989 | | | |
| | B12 | EP 0335386 | 09/02/1992 | | | |
| | B13 | EP 0389282 | 02/20/2002 | | | |
| | B14 | EP 0393500 | 10/24/1990 | | | |
| | B15 | EP 0428302 | 09/24/1997 | | | |
| | B16 | EP 0435811 | 09/01/1993 | | | |
| | B17 | EP 0459505 | 10/02/1996 | | | |
| | B18 | EP 0470805 | 09/07/1994 | | | |

| | | | |
|-------------------------------|--|----------------------------|--|
| Examiner Signature | | Date Considered | |
|-------------------------------|--|----------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO Patent Documents as www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 13

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/817,312 |
| Filing Date | April 1, 2004 |
| First Named Inventor | Stephen S. Palmer |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 05558.0011.NPUS04 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|--|--------------------------------|---|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | B19 | EP 0490823 | 06/17/1992 | | | |
| | B20 | EP 0506194 | 08/21/1996 | | | |
| | B21 | EP 0510562 | 10/28/1992 | | | |
| | B22 | EP 0511865 | 11/04/1992 | | | |
| | B23 | EP 0527117 | 02/10/1993 | | | |
| | B24 | EP 0553174 | 08/04/1993 | | | |
| | B25 | EP 0557016 | 08/25/1993 | | | |
| | B26 | EP 0626939 | 12/07/1994 | | | |
| | B27 | EP 0664289 | 07/26/1995 | | | |
| | B28 | EP 0671389 | 09/13/1995 | | | |
| | B29 | EP 0685474 | 09/16/1998 | | | |
| | B30 | EP 0685475 | 01/13/1999 | | | |
| | B31 | EP 0685479 | 01/13/1999 | | | |
| | B32 | EP 0736532 | 05/15/2002 | | | |
| | B33 | EP 0738715 | 01/29/2003 | | | |
| | B34 | EP 0748805 | 04/08/1998 | | | |
| | B35 | EP 0763534 | 02/26/2003 | | | |
| | B36 | EP 0816357 | 01/09/2002 | | | |
| | B37 | EP 0819688 | 01/21/1998 | | | |
| | B38 | EP 0819689 | 01/21/1998 | | | |
| | B39 | EP 0832886 | 11/13/2002 | | | |
| | B40 | EP 0834508 | 08/16/2001 | | | |
| | B41 | EP 0848000 | 08/03/1983 | | | |
| | B42 | EP 0470805 | 09/07/1994 | | | |
| | B43 | EP 0103497 | 09/20/1989 | | | |
| | B44 | JP 92234389 | 08/24/1992 | | | |
| | B45 | JP 94329652 | 11/29/1994 | | | |
| | B46 | JP 95010875 | 01/13/1995 | | | |
| | B47 | JP 98072415 | 03/17/1998 | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 13

Complete if Known

| | |
|-------------------------------|-------------------|
| Application Number | 10/817,312 |
| Filing Date | April 1, 2004 |
| First Named Inventor | Stephen S. Palmer |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 05558.0011.NPUS04 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD- YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|--|---------------------------------------|--|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | B48 | JP 98147585 | 06/02/1998 | | | |
| | B49 | WO 02/083239 | 10/24/2002 | Ares Trading S.A. | | |
| | B50 | WO 02/083241 | 10/24/2002 | Ares Trading S.A. | | |
| | B51 | WO 03/051344 | 06/26/2003 | Applied Research Ssystems ARS Holding, N.V. | | |
| | B52 | WO 91/17991 | 11/28/1991 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B53 | WO 92/00968 | 01/23/1992 | Smith-Kline Beecham Corporation | | |
| | B54 | WO 92/12961 | 08/06/1992 | Rhone Poulenc Rorer Limited | | |
| | B55 | WO 93/07124 | 04/15/1993 | Eisai Co., Ltd. | | |
| | B56 | WO 93/07146 | 04/15/1993 | Syntex Inc. | | |
| | B57 | WO 93/15044 | 08/05/1993 | Smith-Kline Beecham Corporation | | |
| | B58 | WO 93/15045 | 08/05/1993 | Smith-Kline Beecham Corporation | | |
| | B59 | WO 93/18024 | 09/16/1993 | Rhone-Poulenc Rorer Limited | | |
| | B60 | WO 93/19068 | 09/30/1993 | Syntex Inc. | | |
| | B61 | WO 93/19720 | 10/14/1993 | Smith-Kline Beecham Corporation | | |
| | B62 | WO 93/19747 | 10/14/1993 | Smith-Kline Beecham Corporation | | |
| | B63 | WO 93/19749 | 10/14/1993 | Smith-Kline Beecham Corporation | | |


| | | | |
|-------------------------------|--|----------------------------|--|
| Examiner Signature | | Date Considered | |
|-------------------------------|--|----------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | |
|---|---|----|-------------------------------|-------------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/817,312 |
| | | | Filing Date | April 1, 2004 |
| | | | First Named Inventor | Stephen S. Palmer |
| | | | Group Art Unit | |
| | | | Examiner Name | |
| Sheet | 4 | 13 | Attorney Docket Number | 05558.0011.NPUS04 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|---------------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD- YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | B64 | WO 93/19751 | 10/14/1993 | Smith-Kline Beecham Corporation | | |
| | B65 | WO 93/25517 | 12/23/1993 | Celltech Limited | | |
| | B66 | WO 94/02465 | 02/03/1994 | Rhone-Poulenc Rorer Limited | | |
| | B67 | WO 94/12461 | 06/09/1994 | Pfizer Inc. | | |
| | B68 | WO 94/20455 | 09/15/1994 | Celltech Limited | | |
| | B69 | WO 94/22852 | 10/13/1994 | Syntex Inc. | | |
| | B70 | WO 94/27947 | 12/08/1994 | Rhone-Poulenc Rorer Limited | | |
| | B71 | WO 95/19978 | 07/27/1995 | Laboratoires Glaxo S.A. | | |
| | B72 | WO 95/01338 | 01/12/1995 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B73 | WO 95/01980 | 01/19/1995 | Pfizer Inc. | | |
| | B74 | WO 95/04045 | 02/09/1995 | Rhone-Poulenc Rorer Limited | | |
| | B75 | WO 95/04046 | 02/09/1995 | Rhone-Poulenc Rorer Limited | | |
| | B76 | WO 95/05113 | 02/23/1995 | Block Medizintechnik GMBH | | |
| | B77 | WO 95/05386 | 02/23/1995 | Smithkline Beechem Corporation | | |
| | B78 | WO 95/08534 | 03/30/1995 | Glaxo Inc. | | |
| | B79 | WO 95/09623 | 04/13/1995 | Smithkline Beechem Corporation | | |
| | B80 | WO 95/09624 | 04/13/1995 | Smithkline Beechem Corporation | | |
| | B81 | WO 95/09627 | 04/13/1995 | Smithkline Beechem Corporation | | |


| | | | |
|-------------------------------|--|----------------------------|--|
| Examiner Signature | | Date Considered | |
|-------------------------------|--|----------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional): ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 13

Complete if Known

| | |
|-------------------------------|-------------------|
| Application Number | 10/817,312 |
| Filing Date | April 1, 2004 |
| First Named Inventor | Stephen S. Palmer |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 05558.0011.NPUS04 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD- YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|--|---------------------------------------|--|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | B82 | WO 95/09836 | 04/13/1995 | Smithkline Beechem Corporation | | |
| | B83 | WO 95/14667 | 06/01/1995 | Pfizer, Inc. | | |
| | B84 | WO 95/14680 | 06/01/1995 | Pfizer, Inc. | | |
| | B85 | WO 95/14681 | 06/01/1995 | Pfizer, Inc. | | |
| | B86 | WO 95/17392 | 06/29/1995 | Celltech Therapeutics Limited | | |
| | B87 | WO 95/17399 | 06/29/1995 | Celltech Therapeutics Limited | | |
| | B88 | WO 95/19362 | 07/20/1995 | Pfizer, Inc. | | |
| | B89 | WO 95/20578 | 08/03/1995 | Rhone-Poulenc Rorer Limited | | |
| | B90 | WO 95/22520 | 08/24/1995 | American Home Products Corporation | | |
| | B91 | WO 95/24381 | 09/14/1995 | Smithkline Beechem Corporation | | |
| | B92 | WO 95/27692 | 10/19/1995 | Smithkline Beechem Corporation | | |
| | B93 | WO 95/35281 | 12/28/1995 | Celltech Therapeutics Limited | | |
| | B94 | WO 95/35283 | 12/28/1995 | Celltech Therapeutics Limited | | |
| | B95 | WO 95/35284 | 12/28/1995 | Celltech Therapeutics Limited | | |
| | B96 | WO 96/26940 | 09/06/1996 | Kyowa Hakko Kogyo Co., Ltd. | | |
| | B97 | WO 96/00218 | 01/04/1996 | Euro-Celtique, S.A. | | |

| | | | |
|-------------------------------|--|----------------------------|--|
| Examiner Signature | | Date Considered | |
|-------------------------------|--|----------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 13

Complete if Known

| | |
|-------------------------------|-------------------|
| Application Number | 10/817,312 |
| Filing Date | April 1, 2004 |
| First Named Inventor | Stephen S. Palmer |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 05558.0011.NPUS04 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|-------------------------|-----------------------------|---|---|----------------|
| | B98 | WO 96/01825 | 01/25/1996 | Fujisawa Pharmaceutical Co., Ltd. | | |
| | B99 | WO 96/03399 | 02/08/1996 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B100 | WO 96/06843 | 03/07/1996 | Yamanouchi Pharmaceutical, Inc. | | |
| | B101 | WO 96/11690 | 04/25/1996 | Institut de Recherche Jouveinal | | |
| | B102 | WO 96/11917 | 04/25/1996 | Euro-Celtiuge, S.A. | | |
| | B103 | WO 96/12720 | 05/02/1996 | Pfizer, Inc. | | |
| | B104 | WO 96/31486 | 10/10/1996 | Janssen Pharmaceutica N.V. | | |
| | B105 | WO 96/31487 | 10/10/1996 | Janssen Pharmaceutica N.V. | | |
| | B106 | WO 96/35683 | 11/14/1996 | Nippon Kayaku Kabushiki Kaisha | | |
| | B107 | WO 96/36595 | 11/21/1996 | Chiroscience Limited | | |
| | B108 | WO 96/36596 | 11/21/1996 | Chiroscience Limited | | |
| | B109 | WO 96/36611 | 11/21/1996 | Chiroscience Limited | | |
| | B110 | WO 96/36625 | 11/21/1996 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B111 | WO 96/36626 | 11/21/1996 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B112 | WO 96/36638 | 11/21/1996 | Chiroscience Limited | | |
| | B113 | WO 96/38150 | 12/05/1996 | Smithkline Beecham Corporation | | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 13

Complete if Known

| | |
|-------------------------------|-------------------|
| Application Number | 10/817,312 |
| Filing Date | April 1, 2004 |
| First Named Inventor | Stephen S. Palmer |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 05558.0011.NPUS04 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|-------------------------|--------------------------------|--|---|----------------|
| | B114 | WO 96/39408 | 12/12/1996 | Pfizer Inc. | | |
| | B115 | WO 96/40636 | 12/19/1996 | Pfizer Inc. | | |
| | B116 | WO 97/15561 | 05/01/1997 | Scherin Aktiengesellschaft | | |
| | B117 | WO 97/03967 | 02/06/1997 | Rhone-Poulenc Rorer Limited | | |
| | B118 | WO 97/04779 | 02/13/1997 | Chiroscience Limited | | |
| | B119 | WO 97/05105 | 02/13/1997 | Pfizer Inc. | | |
| | B120 | WO 97/08143 | 03/06/1997 | Celgene Corporation | | |
| | B121 | WO 97/09345 | 03/13/1997 | St. Jude Children's Research Hospital | | |
| | B122 | WO 97/12895 | 04/10/1997 | Japan Science and Technology Corporation | | |
| | B123 | WO 97/18208 | 05/22/1997 | Sandoz-Patent-GMBH | | |
| | B124 | WO 97/19078 | 05/29/1997 | Yamanouchi Pharmaceutical Co., Ltd. | | |
| | B125 | WO 97/20833 | 06/12/1997 | Chiroscience Limited | | |
| | B126 | WO 97/22585 | 06/26/1997 | Merck Frosst Canada Inc. | | |
| | B127 | WO 97/22586 | 06/26/1997 | Merck Frosst Canada Inc. | | |
| | B128 | WO 97/23457 | 07/03/1997 | Celgene Corporation | | |
| | B129 | WO 97/23460 | 07/03/1997 | Celltech Therapeutics Limited | | |
| | B130 | WO 97/23461 | 07/03/1997 | Celltech Therapeutics Limited | | |
| | B131 | WO 97/24117 | 07/10/1997 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | | |
| | B132 | WO 97/24355 | 07/10/1997 | Fujisawa Pharmaceutical Co., Ltd. | | |


| | | | |
|-------------------------------|--|----------------------------|--|
| Examiner Signature | | Date Considered | |
|-------------------------------|--|----------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | |
|---|----|-------------------------------|-------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/817,312 |
| | | Filing Date | April 1, 2004 |
| | | First Named Inventor | Stephen S. Palmer |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 8 | 13 | Attorney Docket Number | 05558.0011.NPUS04 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|-------------------------|-----------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | B133 | WO 97/25312 | 07/17/1997 | Schering Aktiengesellschaft | | |
| | B134 | WO 97/28131 | 08/07/1997 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B135 | WO 97/30999 | 08/28/1997 | Chiroscienc Limited | | |
| | B136 | WO 97/31000 | 08/28/1997 | Chiroscience Limited | | |
| | B137 | WO 97/32853 | 09/12/1997 | Novartis AG | | |
| | B138 | WO 97/35854 | 10/02/1997 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B139 | WO 97/36905 | 10/09/1997 | Institut de Recherche Jouveinal | | |
| | B140 | WO 97/43288 | 11/20/1997 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B141 | WO 97/44036 | 11/27/1997 | Chiroscience Limited | | |
| | B142 | WO 97/44322 | 11/27/1997 | Chiroscience Limited | | |
| | B143 | WO 97/47604 | 12/18/1997 | Nikken Chemicals Co., Ltd. | | |
| | B144 | WO 97/48697 | 12/24/1997 | Rhone-Poulenc Rorer Limited | | |
| | B145 | WO 98/04534 | 05/02/1998 | Nikken Chemicals Co., Ltd. | | |
| | B146 | WO 98/05327 | 02/12/1998 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | | |
| | B147 | WO 98/06692 | 02/19/1998 | Celgene Corporation | | |
| | B148 | WO 98/06704 | 02/19/1998 | Merck Patent GMBH | | |


| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | |
|---|---|-----------------------------|-------------------------------|-------------------|
| Substitute for form 1449B/PTO | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/817,312 | |
| | | Filing Date | April 1, 2004 | |
| | | First Named Inventor | Stephen S. Palmer | |
| | | Group Art Unit | | |
| | | Examiner Name | | |
| Sheet | 9 | 13 | Attorney Docket Number | 05558.0011.NPUS04 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|-------------------------|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | B149 | WO 98/07715 | 02/26/1998 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B150 | WO 98/08828 | 03/05/1998 | Nikken Chemicals Co., Ltd. | | |
| | B151 | WO 98/08830 | 03/05/1998 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B152 | WO 98/08841 | 03/05/1998 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B153 | WO 98/08844 | 03/05/1998 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B154 | WO 98/09946 | 03/12/1998 | Asta Medica Aktiengesellschaft | | |
| | B155 | WO 98/09961 | 03/12/1998 | Pfizer Inc. | | |
| | B156 | WO 98/11113 | 03/19/1998 | Euro-celtique, S.A. | | |
| | B157 | WO 98/14448 | 04/09/1998 | Kyorin Pharmaceutical Co., Ltd. | | |
| | B158 | WO 98/18796 | 05/07/1998 | Novartis AG | | |
| | B159 | WO 98/21208 | 05/22/1998 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B160 | WO 98/22453 | 05/28/1998 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|---|----|----|-------------------------------|-------------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/817,312 |
| | | | Filing Date | April 1, 2004 |
| | | | First Named Inventor | Stephen S. Palmer |
| | | | Group Art Unit | |
| | | | Examiner Name | |
| Sheet | 10 | 13 | Attorney Docket Number | 05558.0011.NPUS04 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|-------------------------|--------------------------------|---|---|----------------|
| | B161 | WO 98/31674 | 07/23/1998 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B162 | WO 98/40382 | 09/17/1998 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B163 | WO 98/45268 | 10/15/1998 | Pfizer Inc. | | |
| | B164 | WO 98/55481 | 12/10/1998 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B165 | WO 98/56756 | 12/17/1998 | Cheil Jedang Corporation | | |
| | B166 | WO 99/05111 | 02/04/1999 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B167 | WO 99/05112 | 02/04/1999 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B168 | WO 99/05113 | 02/04/1999 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B169 | WO 99/06404 | 02/11/1999 | Almirall Prodesfarma | | |
| | B170 | WO 99/18095 | 04/15/1999 | Merck Frosst Canada Inc. | | |
| | B171 | WO 99/31071 | 06/24/1999 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |
| | B172 | WO 99/31090 | 06/24/1999 | Byk Gulden Lomberg Chemische Fabrik GMBH | | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | |
|---|----|-------------------------------|-------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/817,312 |
| | | Filing Date | April 1, 2004 |
| | | First Named Inventor | Stephen S. Palmer |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 11 | 13 | Attorney Docket Number | 05558.0011.NPUS04 |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² |
| | C1 | Ahn, et al., "Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases With Oral Antihypertensive Activity," J. Med. Chem., Volume 40, pp. 2196-2210 (1997) | |
| | C2 | Ashton, et al., "Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents, etc." J. Med. Chem. Volume 37, pp. 1696-1703 (1994) | |
| | C3 | Christensen, et al., "1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosphodiesterase 4 for the Treatment of Asthma," J. Med. Chem., Volume 41, pp. 821-835 (1998) | |
| | C4 | Cleland, et al., "Emerging Protein Delivery Methods," Curr Opin Biotechnol., Volume 12, pp. 212-219 (2001) | |
| | C5 | Corbin, et al., "S.H., Pharmacology of Phosphodiesterase-5 Inhibitors," International Journal of Clinical Practice, Volume 56 No. 6, pp. 453-459 (2002) | |
| | C6 | Fares, et al., "Design a Long-Acting Follitropin Agonist by Fusing the C-Terminal Sequence of the Chorionic Gonadotropin β subunit to the Follitropin β Subunit," Proc. National Acad. Sci., Volume 89, pp. 4304-4308 (1992) | |
| | C7 | Healy, et al., "Female Infertility: Causes and Treatment," Lancet, Vol. Volume 343, pp. 1539-1544 (1994) | |
| | C8 | Jiang, et al., "Furoyl and Benzofuroyl Pyrroloquinolones as Potent and Selective PDE5 Inhibitors for Treatment of Erectile Dysfunction," J. Medical Chem., Vol. 46, pp. 441-444 (2003) | |


| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | | |
|-------|----|----|
| Sheet | 12 | 13 |
|-------|----|----|

Complete if Known

| | |
|-------------------------------|-------------------|
| Application Number | 10/817,312 |
| Filing Date | April 1, 2004 |
| First Named Inventor | Stephen S. Palmer |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 05558.0011.NPUS04 |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| | C9 | Karsa, et al., "Encapsulation and Controlled Release," The Royal Society of Chemistry (1993) | |
| | C10 | Klein, et al., "Development and Characterization of a Long-Acting Recombinant hFSH Agonist," Human Reproduction, Vol. 18, No. 1, pp. 50-56 (2003) | |
| | C11 | Klein, et al., "Pharmacokinetics and Pharmacodynamics of Single-Chain Recombinant Human Follicle-Stimulating Hormone Containing the Human Chorionic Gonadotropin Carboxyterminal Peptide in the Rhesus Monkey," Fertility and Sterility, Vol. 77, No. 6, pp. 1248-1255 (2002) | |
| | C12 | LaPolt, et al., "Enhanced Stimulation of Follicle Maturation and Ovulatory Potential by Long Acting Follicle-Stimulating Hormone Agonists with Extended Carboxyl-Terminal Peptides," Endocrinology, Vol. 131, No. 6, p. 2514-2520 (1992) | |
| | C13 | Luo, et al., "Novel Biomaterials for Drug Delivery," Expert Opinion Ther. Patents, Volume 11, pp. 1395-1410 (2001) | |
| | C14 | Matzuk, et al., "The Biological Role of the Carboxyl-Terminal Extension of Human Chorionic Gonadotropin β -Subunit," Endocrinology, Vol. 126, No. 1, pp. 376-383 (1990) | |
| | C15 | Rotella, et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction," J. Med. Chem, Vol. 43, pp. 1257-1263 (2000) | |
| | C16 | Terrett, et al., "Sildenafil (Viagra™), A Potent and Selective Inhibitor of Type 5 CGMP Phosphodiesterase with Utility For the Treatment of Male Erectile Dysfunction," Bioorganic and Medicinal Chemistry Letters, Vol. 6, No. 15, pp. 1819-1824 (1996) | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | |
|---|----|-----------------------------|-------------------------------|-------------------|
| Substitute for form 1449B/PTO | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/817,312 | |
| | | Filing Date | April 1, 2004 | |
| | | First Named Inventor | Stephen S. Palmer | |
| | | Group Art Unit | | |
| | | Examiner Name | | |
| Sheet | 13 | 13 | Attorney Docket Number | 05558.0011.NPUS04 |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² |
| | C17 | Thompson, et al., "Assay of Cyclic Nucleotide Phosphodiesterase and Resolution of Multiple Molecular Forms of the Enzyme," Advances in Cyclic Nucleotide Research, Vol. 10, pp. 69-92 (1979) | |
| | C18 | Wiersma, et al., "Phosphodiesterase 3 Inhibitors Suppress Oocyte Maturation and Consequent Pregnancy Without Affecting Ovulation and Cyclicity in Rodents," J. Clin. Invest., Vol. 102, No. 3, pp. 532-537 (1998) | |
| | C19 | Yacobi, et al., 1998, Oral Sustained Release Formulations: Design and Evaluation, Eva Halperin-Walega (Editor), 1st Ed.; Pergamon Press (1998) | |
| | C20 | Physician's Desk Reference, PDR™, 57 th Ed. pages 2653-2656 (2003) | |
| | C21 | Physician's Desk Reference, PDR™, 52 nd Ed. pages 1949-1951 (1998) | |
| | C22 | Physician's Desk Reference, PDR™, 52 nd Ed. Pages 2771-2773 (1998) | |
| | C23 | Physician's Desk Reference, PDR™, 52 nd Ed. Pages 2773-2775 (1998) | |
| | C24 | Physician's Desk Reference, PDR™, 57 th Ed. pages 2401 (2003) | |
| | C25 | Physician's Desk Reference, PDR™, 57 th Ed. pages 2994 (2003) | |
| | C26 | Physician's Desk Reference, PDR™, 57 th Ed. pages 695 (2003) | |
| | C27 | Physician's Desk Reference, PDR™, 57 th Ed. pages 1324-1325 (2003) | |
| | C28 | Physician's Desk Reference, PDR™, 57 th Ed. pages 1325-1327 (2003) | |
| | C29 | Physician's Desk Reference, PDR™, 57 th Ed. pages 3119-3121 (2003) | |
| | C30 | Physician's Desk Reference, PDR™, 57 th Ed. pages 3124-3128 (2003) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.